logo
  

Xylem Q3 Adj. Profit Tops View - Quick Facts

Xylem Inc. (XYL), a global water technology company, posted third quarter net income of $106 million or $0.58 per share, compared to $73 million or $0.39 per share in the year ago quarter.

Adjusted net income for the latest third quarter was $97 million or $0.53 per share, up from $92 million or $0.49 per share in the prior year quarter.

Revenue for the latest third quarter was was $963 million, down from $965 million in the prior year period.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.52 per share and revenues of $982.06 million for the quarter. Analysts' estimates typically exclude special items.

Xylem narrowed its earnings guidance, and now expects adjusted earnings per share of $1.92 to $1.98, reflecting 15 to 19 percent growth over 2013. Full-year 2014 revenue is still expected to be approximately $4 billion, up 2% versus the prior year.

Wall Street currently is looking for fiscal year 2014 earnings of $1.95 per share on annual revenues of $3.95 billion.

Earlier, the company expected full-year adjusted earnings in the range of $1.90 to $2.00 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT